What are the responsibilities and job description for the Join Our Talent Community position at ReCode Therapeutics?
Who We Are:
ReCode Therapeutics is a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics. ReCode's proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables highly precise and targeted delivery of genetic medicines directly to the organs, tissues and cells implicated in disease, enabling improved efficacy and potency. ReCode's lead programs include RCT1100 for the treatment of primary ciliary dyskinesia caused by pathogenic mutations in the DNAI1 gene, and RCT2100 for the treatment of the 10-13% of cystic fibrosis patients who have Class I mutations in the CFTR gene and do not respond to currently approved CFTR modulators. RCT1100 and RCT2100 are inhaled disease-modifying mRNA-based therapies formulated using the SORT LNP delivery platform. ReCode is expanding its pipeline to develop potential therapies for other rare and common genetic diseases, including musculoskeletal, central nervous system, liver and infectious disease indications.
Don't see an opening that aligns with your expertise and interest? We encourage you to submit your resume, and let us know what areas you're interested in. We'll keep you informed of opportunities that arise in the future!
Benefits Offered for Full-Time Employees:
ReCode Therapeutics is an Equal Opportunity Employer.
ReCode Therapeutics is a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics. ReCode's proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables highly precise and targeted delivery of genetic medicines directly to the organs, tissues and cells implicated in disease, enabling improved efficacy and potency. ReCode's lead programs include RCT1100 for the treatment of primary ciliary dyskinesia caused by pathogenic mutations in the DNAI1 gene, and RCT2100 for the treatment of the 10-13% of cystic fibrosis patients who have Class I mutations in the CFTR gene and do not respond to currently approved CFTR modulators. RCT1100 and RCT2100 are inhaled disease-modifying mRNA-based therapies formulated using the SORT LNP delivery platform. ReCode is expanding its pipeline to develop potential therapies for other rare and common genetic diseases, including musculoskeletal, central nervous system, liver and infectious disease indications.
Don't see an opening that aligns with your expertise and interest? We encourage you to submit your resume, and let us know what areas you're interested in. We'll keep you informed of opportunities that arise in the future!
Benefits Offered for Full-Time Employees:
- No premium cost for employees - 100% subsidized by ReCode for full-time employees
- Company 401k contribution
- 15 days of company paid holidays, including a holiday shutdown (usually the last week of the year)
- Mental health support for employees & their families
- FSA available, including a lifestyle spending account subsidized by company
- Employee discounts at hotspots
ReCode Therapeutics is an Equal Opportunity Employer.